Glenmark Pharmaceuticals Ltd
NSE: GLENMARK BSE: 532296
₹2136.70
(0.58%)
Sun, 08 Mar 2026, 03:16 pm
Market Cap603.26B
PE Ratio56.64
Dividend0.23
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1977
- Incorporated on November 18 as Glenmark Pharmaceuticals Private Limited.
1979
- Entered anti-fungal market with Candid Cream.
- Launched Candid Lotion, Candid V-3, Candid V-1, Candid V-Gel.
1981
- Launched Candid-B Cream.
1985
- Launched Candid Mouth Paint.
- Launched Ascoril cough expectorant.
1987
- Started Research and Development Department at Nasik factory.
1990
- Became deemed public company on July 1.
- Became private company on September 27.
- Launched Candiderma.
1991
- Deleted 'Private' from name on July 1.
1993
- Launched Candid Ear Drops.
- Proposed ERP system implementation with Sales, Distribution, Finance, Production, and MRP modules.
1995
- Launched Candid TV Suspension and Candidtral.
- Created Glenmark Pharmaceuticals Limited Employee Welfare Trust for ESOP.
1996
- Became Public Limited Company on January 12.
1997
- Established Cardiac Center in Dadar, Mumbai.
- Proposed drug discovery center in Thane-Belapur.
1999
- Proposed line extensions, new products, and Canada subsidiary.
- Allotted 175,000 warrants to Employee Welfare Trust.
- Launched Altacef, Suprocin, Suprocin B, Scalpe, Elovera.
- Public issue of 2,670,000 equity shares at Rs 200.
- Set up soft gel capsule facility in Goa and R&D center in Mumbai.
2000
- Shares listed on BSE at Rs 550.
- Entered strategic alliance with Haller Group Brazil.
- Issued 3,000,000 equity shares via private placement.
- Increased borrowing powers to Rs 150 crores.
- Acquired Alex, Flucort, and Sensur brands from Lyka Labs.
2001
- Board proposed private placement of 4,000,000 redeemable cumulative non-convertible preference shares.
2002
- Established proof of concept in animals for GRC-1087 anti-diabetic/anti-obesity agent.
- Co-opted Rajiv V Desai, A S Mohanty, and Sameer Paigankar to board.
- Robin Pinto resigned as director.
- CDC Financial Services acquired 2,500,000 convertible debentures.
2003
- Approved disinvestment of Goa manufacturing facilities.
- Forayed into US generics market.
- Declared 65% interim dividend.
- Allotted 21,000 ESOP equity shares.
- Entered marketing arrangement with Lannett Company US.
- Approved sub-division of equity shares from Rs 10 to Rs 2.
- Submitted Initial Drug Master File for Amiodarone.
- Fire at Kurkum factory suspended operations.
- Tied up with Apotex Canada for cardiac bulk drug supply.
- Converted debentures into 818,557 equity shares at Rs 305.42.
2004
- Glenmark Pharmaceuticals Inc. USA signed development and marketing agreement with KV Pharmaceutical.
- Acquired Laboratories Klinger in Brazil for $5.2 million.
- Acquired two FDA-approved products from Clonmel Healthcare Ltd.
- Glenmark Pharmaceuticals SA entered collaboration with Forest Laboratories for GRC 3886.
2005
- Forged alliance with 2 US firms for US product sales.
- Announced collaboration with Teijin Pharma on GRC 3886.
- Glenmark Pharmaceuticals SA acquired Servycal SA in Argentina.
- Signed development and marketing agreement with InvaGen.
- Issued 1:1 bonus.
2006
- Glenmark USA acquired exclusive marketing rights to 3 generic products.
- Signed $27 million royalty deal with Paul Capital for US generic dermatology portfolio.
- US subsidiary inked agreement with Lehigh.
- Planned acquisition of generic company in Europe.
- Joined hands with US firm.
2007
- Received tentative USFDA approval for Topiramate Tablets.
- Received MHRA UK approval for Baddi semi-solids plant.
- Out-licensed GRC 6211 to Eli Lilly for $350 million deal.
- Split face value from Rs 2 to Rs 1.
2008
- Launched Nabumetone and Hydroxyzine Hydrochloride Tablets.
- Launched Clobetasol from dermatology pipeline.
- Launched trandolapril tablets.
- Subsidiary received USFDA approval for Betamethasone Dipropionate Cream 0.05% Augmented.
2009
- M J Mendonza joined as VP Legal & Company Secretary.
- Received ANDA approval for Alclometasone Dipropionate Cream 0.05%.
- Appointed D R Mehta and B E Saldanha as Additional Directors.
- Received ANDA approval for Verapamil 240 mg ER tablets.
2010
- Entered settlement and license agreement with Sepracor for generic Eszopiclone tablets.
2011
- Won two SCRIP Awards.
- Exercised purchase option in royalty agreement with Paul Capital.
- Forayed into Cosmeceutical Segment.
- GBR 500 deal cleared under Hart-Scott-Rodino Act.
2012
- Signed development agreement with Forest Laboratories for novel agents treating chronic inflammatory conditions.
- Settled Paragraph IV litigation with Janssen Pharmaceuticals.
- Received tentative approval for zolmitriptan orally disintegrating tablets.
- Won arbitration claim against Napo.
2013
- Launched Hydrocortisone Butyrate cream in US.
- Announced discovery and IND-enabling studies of OX40-targeting monoclonal antibody.
- USFDA approved Crofelemer 125 mg delayed-release tablets for HIV/AIDS diarrhea.
- Received ANDA approval for Mupirocin Calcium Cream USP 2%.
- Atovaquone Proguanil (Malarone) patent revoked; launched first UK generic.
- Initiated IND-enabling studies of novel monoclonal antibody.
2014
- Merged subsidiaries Glenmark Generics Ltd. and Glenmark Access Ltd. with Glenmark Pharmaceuticals Ltd.
- Entered Oncology with discovery of bispecific Antibody.
- Inaugurated Antibody Manufacturing Facility in La Chaux-de-Fonds, Switzerland.
- USFDA granted final ANDA acceptance.
- Received $5 million milestone payment from Sanofi for VLA2 monoclonal antibody.
- Received USFDA approval for skin infection cream.
2015
- Approved and launched Ashlyna Extended-Cycle Oral Contraceptive Tablets in US.
- Approved and launched Trandolapril & Verapamil HCl ER Tablets in US.
- Received USFDA approval for Salmecort MDI Inhaler in Russia.
- CCEA approved foreign investment proposals worth Rs 4187 crore.
- Certified Scheme of Arrangement merging Glenmark Generics Ltd. and Glenmark Access Ltd. with Glenmark Pharmaceuticals Ltd.
- Announced strategic development and licensing agreement with Celon Poland for generic Seretide Accuhaler in Europe.
- Received tentative ANDA approval for Lacosamide Tablets 50 mg, 100 mg, 150 mg, 200 mg.
- Received ANDA approval for Clotrimazole and Betamethasone Dipropionate Cream USP 1%/0.05%.
- Entered settlement agreement with Forest Laboratories and Royalty Pharma.
2016
- Received tentative USFDA approval for anti-arrhythmic drug.
- Discovered new molecule.
- Received USFDA approval for cancer treatment drug.
- Received approval for Raloxifene tablets.
- Received 3 USFDA observations for Indore plant.
- Received approval for Triamcinolone Acetonide Ointment.
- Launched first generic Zetia in US.
- Received approval for Tretinoin Capsules.
2017
- Announced partnership with Evestra for generic NuvaRing.
- Entered agreement with APC Therapeutics.
- Entered exclusive agreement with Cyndea Pharma for generic soft-gelatin capsules.
- Launched nicotine substitute gum.
2018
- Launched Nourkrin in Russia.
- Launched biosimilar Adalimumab in India.
- Entered exclusive collaboration with SCD Pharmaceuticals South Korea for ophthalmic products.
- Launched generic Seretide Accuhaler in Denmark.
- Collaborated with True North for orthopaedic and pain management business in India.
2019
- Entered licensing agreement with Yuhan for Ryaltris in South Korea.
- Signed licensing agreement with Torrent for co-marketing Remogliflozin Etabonate in India.
- Secured Dow Jones Sustainability Emerging Markets Index for second year.
2020
- First to launch Remogliflozin + Vildagliptin FDC for Type 2 Diabetes in India.
- Introduced NINDANIB (Nintedanib) for Pulmonary Fibrosis in India.
- Introduced 400 mg strength FabiFlu for COVID-19 treatment.
- Received USFDA approval for Deferasirox tablets for oral suspension.
- Pledged 50 lakh meals amid COVID-19 pandemic.
- Entered exclusive licensing agreement with Hikma for Ryaltris in US.
2021
- Awarded International Safety Award.
- Awarded Environmental, Social and Governance Summit & Awards.
- Launched Rufinamide Tablets USP 200 mg and 400 mg.
- Launched Ryaltris nasal spray in India.
2022
- Received USFDA approval for Nicardipine Hydrochloride capsules.
- Received ANDA approval for generic birth control drug.
- Received India Pharma Innovation of the Year Award from Government of India.
- First to launch Triple FDC Teneligliptin + Pioglitazone + Metformin for Type 2 Diabetes in India.
- Launched Fingolimod Capsules 0.5 mg in US.
2023
- Launched Bumetanide Injection USP 1 mg/4 mL and 2.5 mg/10 mL in US.
2024
- Received US health regulator approval for generic stomach acid medication.
- Launched Lacosamide Oral Solution 10 mg/mL in US.
- Launched Travoprost Ophthalmic Solution USP 0.004% in US.
- Received ANDA approval for Topiramate Capsules USP 15 mg and 25 mg.
- Entered agreement with BeiGene for marketing and distribution of Tislelizumab and Zanubrutinib in India.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800